Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Acrivon Therapeutics, Inc.

NASDAQ: ACRV · Life Sciences · 4 alerts · CIK 1781174

Share price
$1.46Close, Nov 16
Market cap
$62.7M
Shares outstanding
42.91MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Acrivon Therapeutics, Inc. filings on SEC EDGAR ↗

8:00 AM ET 8-K
M&A Deal

Acrivon Therapeutics M&A Deal with Aqilion AB

Acrivon Therapeutics has acquired a portfolio of immunology and inflammation (I&I) assets from Swedish biotech Aqilion AB, including the Phase 2-ready oral JAK1 inhibitor ACR-525 and a preclinical PKCθ inhibitor program. The deal establishes I&I as a new strategic pillar for Acrivon, which plans to apply its AP3 precision medicine platform to these assets for indications such as Eosinophilic esophagitis (EoE).

Counterparty
Aqilion AB

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.